Iptacopan (Factor B Inhibitor)
C3 Glomerulopathy
Sponsor Novartis
98 Enrollment Target
45 Trial Sites
4 Countries
September 2026 Est. Completion
About This Trial
Oral Factor B inhibitor for complement-mediated kidney disease.
Primary Endpoints
- Proteinuria reduction
- eGFR stabilization
Latest Update
January 2026
66% of patients achieved >50% proteinuria reduction. BLA under FDA review with PDUFA date August 2026.